ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near London, England, GBR:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Enrolling
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

London, United Kingdom and 157 other locations

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

London, United Kingdom and 42 other locations

and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Nab-paclitaxel
Drug: Gemcitabine

Phase 3

Novartis
Novartis

London, United Kingdom and 113 other locations

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

Phase 2

Genentech
Genentech

London, United Kingdom and 36 other locations

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: oxaliplatin

Phase 3

Astellas
Astellas

London, United Kingdom and 164 other locations

An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is M...

Enrolling
Adenocarcinoma - GEJ
Cancer of Esophagus
Drug: Temozolomide 3 month
Drug: Temozolomide 50mg/m2/day

Phase 2

University of Southampton

Cambridge, Cambridgeshire, United Kingdom

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Evorpacept (ALX148)
Drug: Trastuzumab

Phase 2, Phase 3

ALX Oncology

London, United Kingdom and 54 other locations

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

London, United Kingdom and 212 other locations

mCRPC. Patients enrolled in the Phase 2a portion of the study will have either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma...

Active, not recruiting
Small Cell Carcinoma
Neuroendocrine Tumors
Drug: BXCL701 monotherapy
Drug: BXCL701 plus Pembrolizumab

Phase 1, Phase 2

BioXcel Therapeutics

London, Great Britain, United Kingdom and 11 other locations

The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of...

Enrolling
Locally Advanced Pancreatic Cancer
Device: OncoSil™
Drug: FOLFIRINOX chemotherapy

Phase 2

OncoSil Medical

London, United Kingdom and 15 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems